Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy

Vaccine

Volumn 33, Issue 2, 2015, Pages 388-395

  Miller, Elizabeth ^a   Spadaccia, Meredith ^a   Sabado, Rachel ^a   Chertova, Elena ^b   Bess, Julian ^b   Trubey, Charles Mac ^b   Holman, Rose Marie ^a   Salazar, Andres ^c   Lifson, Jeffrey ^b   Bhardwaj, Nina ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AIDS and Cancer Virus Program   (United States)

^c Washington   (United States)

Author keywords

Dendritic cell; HIV 1; Poly ICLC; Therapeutic vaccine

Indexed keywords

2,2' DITHIODIPYRIDINE; BETA GALACTOSIDASE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; 2,2' BIPYRIDINE; 2,2'-DIPYRIDYL DISULFIDE; CARBOXYMETHYLCELLULOSE; DISULFIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; MYCOPLASMA; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; VIRUS INACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; CELL LINE; CHEMISTRY; DENDRITIC CELL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; PROCEDURES; VIROLOGY;

2,2'-DIPYRIDYL; ADAPTIVE IMMUNITY; AIDS VACCINES; BETA-GALACTOSIDASE; CARBOXYMETHYLCELLULOSE SODIUM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; DISULFIDES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY, ADOPTIVE; POLY I-C; POLYLYSINE; VIRUS INACTIVATION;

EID: 84922348792     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.054     Document Type: Article

References (37)

1. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., Yang H.C., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36(3):491-501.
2. Buisson S., Benlahrech A., Gazzard B., Gotch F., Kelleher P., Patterson S. Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis 2009, 199(12):1862-1871.
3. Frleta D., Ochoa C.E., Kramer H.B., Khan S.A., Stacey A.R., Borrow P., et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 2012, 122(12):4685-4697.
4. Miller E.A., Spadaccia M.R., O'Brien M.P., Rolnitzky L., Sabado R., Manches O., et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr 2012, 61(5):535-544.
5. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27(43):6088-6094.
6. Garcia F., Lejeune M., Climent N., Gil C., Alcami J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005, 191(10):1680-1685.
7. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006, 78(6):711-718.
8. Garcia F., Routy J.P. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29(38):6454-6463.
9. Garcia F., Climent N., Assoumou L., Gil C., Gonzalez N., Alcami J., et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011, 203(4):473-478.
10. Garcia F., Climent N., Guardo A.C., Gil C., Leon A., Autran B., et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Trans Med 2013, 5(166):166ra2.
11. Allard S.D., De Keersmaecker B., de Goede A.L., Verschuren E.J., Koetsveld J., Reedijk M.L., et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat: Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 2012, 142(3):252-268.
12. Van Gulck E., Vlieghe E., Vekemans M., Van Tendeloo V.F., Van De Velde A., Smits E., et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012, 26(4):F1-F12.
13. Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010, 134(2):140-147.
14. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15(2):284-292.
15. Routy J.P., Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2010, 2(4):467-476.
16. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10(12):1359-1365.
17. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998, 70:83-243.
18. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9(1):27-32.
19. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W., Vasquez G.M., et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72(10):7992-8001.
20. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000, 74(18):8358-8367.
21. Platt E.J., Bilska M., Kozak S.L., Kabat D., Montefiori D.C. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 2009, 83(16):8289-8292.
22. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72(4):2855-2864.
23. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46(6):1896-1905.
24. Means R.E., Matthews T., Hoxie J.A., Malim M.H., Kodama T., Desrosiers R.C. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol 2001, 75(8):3903-3915.
25. Del Prete G.Q., Kearney M.F., Spindler J., Wiegand A., Chertova E., Roser J.D., et al. Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol 2012, 86(6):3152-3166.
26. Che K.F., Sabado R.L., Shankar E.M., Tjomsland V., Messmer D., Bhardwaj N., et al. HIV-1 impairs in vitro priming of naive T cells and gives rise to contact-dependent suppressor T cells. Eur J Immunol 2010, 40(8):2248-2258.
27. Lubong Sabado R., Kavanagh D.G., Kaufmann D.E., Fru K., Babcock E., Rosenberg E., et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS ONE 2009, 4(1):e4256.
28. Sabado R.L., Babcock E., Kavanagh D.G., Tjomsland V., Walker B.D., Lifson J.D., et al. Pathways utilized by dendritic cells for binding: uptake, processing and presentation of antigens derived from HIV-1. Eur J Immunol 2007, 37(7):1752-1763.
29. Sabado R.L., O'Brien M., Subedi A., Qin L., Hu N., Taylor E., et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010, 116(19):3839-3852.
30. Larsson M., Fonteneau J.F., Lirvall M., Haslett P., Lifson J.D., Bhardwaj N. Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 2002, 16(10):1319-1329.
31. Lu W., Andrieu J.M. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001, 75(19):8949-8956.
32. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006, 203(5):1249-1258.
33. Zhang Z., Kim T., Bao M., Facchinetti V., Jung S.Y., Ghaffari A.A., et al. DDX1: DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011, 34(6):866-878.
34. Zhang Z., Yuan B., Lu N., Facchinetti V., Liu Y.J. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J Immunol 2011, 187(9):4501-4508.
35. Zobywalski A., Javorovic M., Frankenberger B., Pohla H., Kremmer E., Bigalke I., et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007, 5:18.
36. Bogunovic D., Manches O., Godefroy E., Yewdall A., Gallois A., Salazar A.M., et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011, 71(16):5467-5476.
37. Vagenas P., Aravantinou M., Williams V.G., Jasny E., Piatak M., Lifson J.D., et al. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS ONE 2010, 5(9):e12891.